Medication-related osteonecrosis of the jaw: Analysing the range of implicated drugs from the Australian database of adverse event notifications

Study (n=419) noted that while majority of cases were linked to denosumab or bisphosphonates (n=405), there were 14 reports where secondary agents that directly or indirectly affect bone turnover, were also implicated (adalimumab, etanercept, methotrexate and rituximab).

Source:

British Journal of Clinical Pharmacology